Lifeward Ltd.LFWD
Lifeward Ltd. Commitments Disclosure
NOTE
7:- COMMITMENTS AND CONTINGENT LIABILITIES
| a. |
Purchase commitment: |
The
Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors.
Purchase obligations do not include contracts that may be cancelled without penalty. As of December 31, 2025, non-cancellable outstanding
obligations amounted to approximately $6.0
million.
| b. |
Operating lease commitment:
|
| (i) |
The
Company operates from leased facilities in Israel, the United States and Germany, with leases expiring in 2030. A portion
of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (CPI). The changes to the
CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.
|
| (ii) |
LL
and LG lease cars for their employees under cancellable operating lease agreements expiring at various dates between 2026 and 2028.
A subset of the Company’s cars leases is considered variable. The variable lease payments for such cars leases are based on actual
mileage incurred at the stated contractual rate. LL and LG have an option to be released from these agreements, which may result in penalties
in a maximum amount of approximately $34
thousand as of December 31, 2025. |
The
Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current
operating leases liabilities on the Company’s consolidated balance sheets as of December 31, 2025 are as follows (in thousands):
|
2026
|
$
|
452
|
||
|
2027
|
428
|
|||
|
2028
|
380
|
|||
|
2029
|
358
|
|||
|
2030
|
299
|
|||
|
Total lease payments
|
1,917
|
|||
|
Less: imputed interest
|
(333
|
)
| ||
|
Present value of future
lease payments |
1,584
|
|||
|
Less: current maturities
of operating leases |
(425
|
)
| ||
|
Non-current operating
leases |
$
|
1,159
|
||
|
Weighted-average remaining
lease term (in years) |
4.72
|
|||
|
Weighted-average discount
rate |
8.94
|
%
|
Total
lease expense under the Company’s operating leases for the years ended December 31, 2025, 2024 and 2023 were $0.8
million, $1.3
million, and $1.0
million, respectively.
| c. |
Royalties: |
The
Company’s research and development efforts are financed, in part, through funding from the IIA. Since the Company’s inception
through December 31, 2025, the Company received funding from the IIA in the total amount of $2.8
million. Out of the $2.8
million in funding from the IIA, a total amount of $1.6
million were royalty-bearing grants, $400
thousand was received in consideration of 209
convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary
shares in a conversion ratio of 1 to 1, while $806
thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3%
of the sales of the products and other related revenues generated from such projects, up to 100%
of the grants received. The royalty payment obligations also bear interest at the SOFRPR rate. The obligation to pay these royalties is
contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.
As
of December 31, 2025, the Company paid royalties to the IIA in the total amount of $117
thousand.
Royalties
expenses in cost of revenue were $8
thousand, $2
thousand and $17
thousand, for the years ended December 31, 2025, 2024 and 2023, respectively.
As
of December 31, 2025, the contingent liability to the IIA amounted to $1.6
million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program
may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products
resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside
Israel, in the following cases:
(a)
the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration
for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received
plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed
to retain the R&D activities of the grant recipient in Israel after the transfer); (b)
the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how
arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises
in connection with a liquidation by reason of insolvency or receivership of the grant recipient.
LCAI
earns royalties under a license agreement with a third party and is recognized as earned. Royalty payments for the year ended December
31, 2025 and 2024, were $0
and $55
thousand, respectively.
| d. |
Liens |
As
part of the Company’s restricted cash and other long-term assets, as of December 31, 2025, an amount of $410
thousand has been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or
withdrawn without the consent of such third party.
| e. |
Legal Claims: |
Occasionally,
the Company is involved in various claims such as product liability claims, lawsuits, regulatory examinations, investigations, and other
legal matters arising, for the most part, in the ordinary course of business. While the outcome of any pending or threatened litigation
and other legal matters is inherently uncertain, the Company does not believe the outcome of any of the matters will have a material adverse
effect on the Company’s consolidated results of operation, liquidity or financial condition.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 18, 2026 | Showing above |
| 2024 | Mar 7, 2025 | |
| 2023 | Feb 27, 2024 | |
| 2022 | Feb 23, 2023 | |
| 2021 | Feb 24, 2022 | |
| 2020 | Feb 18, 2021 | |
| 2019 | Feb 20, 2020 | |
| 2018 | Feb 8, 2019 | |
| 2017 | Mar 8, 2018 | |
| 2016 | Feb 17, 2017 | |
| 2015 | Feb 29, 2016 | |
About Commitments Disclosures
Commitments and contingencies disclosures catalog a company's off-balance-sheet obligations and legal exposures — purchase commitments, guarantee arrangements, pending litigation, and regulatory proceedings. These items represent potential future cash outflows that may not appear as liabilities on the balance sheet until they become probable and estimable.
Key signals: litigation reserves and disclosed loss ranges quantify management's estimate of legal exposure, but unquantified "reasonably possible" losses often represent the larger risk. Watch for changes in language around pending cases — shifts from "remote" to "reasonably possible" or increases in estimated loss ranges signal deteriorating outcomes. Unconditional purchase obligations and take-or-pay contracts create fixed cost structures that reduce operational flexibility. Guarantee arrangements for subsidiaries or joint ventures can create cascading obligations. Compare the total commitment schedule against projected free cash flow to assess whether the company can meet its obligations without additional financing.